Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Maurizio Fava, MD
With
Novartis Pharmaceuticals
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent.
Men or women ages 18-65 years old.
Current Major Depressive Episode in partial remission based on the Structured Clinical Interview for DSM IV-Axis I Disorders (SCID I/P) and a HAM-D-17 score between 9 and 15.
Current treatment with a selective serotonin reuptake inhibitor (SSRI) other than paroxetine or fluoxetine for at least three months, at a stable dose for the past 4 weeks, and more than 50% but less than 75% improvement on the current antidepressant, as determined by the MGH Antidepressant Treatment Response Questionnaire (ATRQ).
Score \> 8 on the Anger/Hostility Scale of the Symptom Questionnaire both at screen and baseline.
You may not be if
The following DSM-IV diagnoses: 1) organic mental disorders; 2) substance use disorders, including alcohol, active within the last 3 months; 3) schizophrenia; 4) delusional disorder; 5) psychotic disorders not elsewhere classified; 6) bipolar disorder; and 9) antisocial personality disorder; 10) dementia.
Current, serious suicidal or homicidal risk.
Pregnancy or breast-feeding.
Serious, unstable medical illness including cardiovascular, kidney, liver, neurological and endocrine disorders.
Congenital long QT syndrome or a QTc \> 450 ms.
History of cardiac arrhythmias.
Electroconvulsive therapy (ECT) within the 6 months preceding baseline.
Concomitant use of buspirone, fluoxetine, paroxetine, any psychostimulant, modafinil, other antipsychotic drugs, or anticonvulsants (although stable doses of benzodiazepines and hypnotics are allowed) (see Concomitant Therapy).
Clareo Health | Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability
